Kazia Therapeutics can boast six ongoing clinical trials, all under the oversight of the US FDA, aimed at addressing some of the world's most challenging cancers.

Paxalisib (formerly GDC-0084) inhibits the PI3K pathway that is thought to be critical to the development of certain kinds of tumours.  Paxalisib is currently involved in five clinical trials examining our drug in a range of forms of brain cancer including:

  • Glioblastoma - the most common and most aggressive form of primary brain cancer

  • DIPG - a rare but very aggressive childhood brain cancer

  • Breast cancer brain metastises (BCBM)

  • Two separate trials focussed on cancer which has spread to the brain from any primary source

 

Cantrixil (TRE-E-002-1) is a third-generation benzopyran that targets slower dividing 'tumour-initiating cells' thereby helping combat the problems of resistance and recurrence that occur with chemotherapy.  We are currently in a Phase I study in ovarian cancer, and have recently completed recruitment to Part B of this trial.